Clinical trial · no report yet · Phase 3
ENHANCE-2
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- NCT04778397 ↗
- Terminated
- Gilead Sciences
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 7 | |
| X threads | 5 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Magrolimab; Venetoclax; Azacitidine; Cytarabine; Daunorubicin; Idarubicin; Steroidal Eye Drops
- Arms
- Magrolimab + Azacitidine · Experimental
- Control Arm: Venetoclax + Azacitidine · Active comparator
- Control Arm: 7+3 Chemotherapy · Active comparator
- Enrollment
- 258
- Primary outcomes
- Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy
- Sponsor
- Gilead Sciences
- Start
- Jul 1, 2021
- Primary completion
- Mar 25, 2024
- Results posted
- Yes
- Registry record
- NCT04778397 · updated Feb 5, 2025
Publications
linked from the registry- Zeidner JF, Sallman DA, Recher C, Daver NG, Leung AYH, Hiwase DK, Subklewe M, Pabst T, Montesinos P, Larson RA, Wilde L, Enjeti AK, Kawashima I, Papayannidis C, O'Nions J, Johnson L, Dong M, Huang J, Bagheri T, Hacohen Kleiman G, Lee C, Vyas P. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31;146(5):590-600. doi: 10.1182/blood.2024027408. PubMed 40009500
- Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Nov 1;41(31):4893-4904. doi: 10.1200/JCO.22.02604. Epub 2023 Sep 13. PubMed 37703506